Nachrichten zur Illumina Inc. Aktie

Illuminas SWOT analysis: stock faces pricing headwinds amid market leadership By Investing.com

Illuminas SWOT analysis: stock faces pricing headwinds amid market leadership…

Illumina Aktie: Downgrade

New York (www.aktiencheck.de) - Rating-Update: Patrick Donnelly, Analyst der Citigroup, stuft die Aktie von Illumina Inc. (ISIN: US4523271090, WKN: 927079, Ticker-Symbol:…

Illumina, Inc. (ILMN) CFO Ankur Dhingra Hosts Annual Evercore ISI HealthCONx Healthcare Conference (Transcript)

…

MYGN Stock Up on Integration of HRD Platform Into Illuminas TSO 500 v2

Myriad Genetics incorporates its proprietary HRD platform in Illuminas updated TruSight Oncology 500 v2 comprehensive gene panel assay.…

Illumina, Inc. (ILMN) CFO Ankur Dhingra Hosts Wolfe Research 2024 Healthcare Conference (Transcript)

…

Illumina: Taktgeber in der Genomforschung

Illumina hat sich als Schlüsselspieler in der Genomforschung etabliert und prägt mit seinen Technologien die Möglichkeiten der modernen Medizin.…

Illumina Aktie: Neue Produkte und Wachstumsbeschleunigung in 2025

Little Rock (www.aktiencheck.de) - Illumina-Aktienanalyse von Stephens Inc.: 1. Anpassung des Kursziels und Übergewichtung Stephens Inc. hat das Kursziel für die Aktie…

Illumina coverage resumed at equal weight by Morgan Stanley

…

Illumina: Kursziel verbessert

Milwaukee (www.aktiencheck.de) - Rating-Update: Die Analysten von Robert W. Baird stufen die Aktie von Illumina Inc. (ISIN: US4523271090, WKN: 927079, Ticker-Symbol:…

Illumina, Inc. (ILMN) Q3 2024 Earnings Call Transcript

…

ILMN Q3 Earnings Top, 24 Sales View Down, Stock Dips in Aftermarket

Illuminas third- quarter revenues from the consumables business show robust growth, offset by the declining instruments business.…

Illumina shares fall 5% as Q4 revenue guidance disappoints By Investing.com

Illumina shares fall 5% as Q4 revenue guidance disappoints…

Illuminas Q3 Earnings Coming Up: Time to Buy, Sell or Hold the Stock?

In the third quarter of 2024, ILMN is likely to have benefited from the significant step-up in consumables with growing…

ILMN Stock Trading Near 52-Week High: Should You Buy, Sell or Hold?

Reaching a new one-year high, Illumina remains in investors sight owing to its strong strategic execution and positive growth outlook.…

Doppelter Analystensupport: Illumina (ILMN) könnte von drei Hauptthemen profitieren. Leerink sieht 40 % Aufwärtspotenzial.

Die Aktie von Illumina (ILMN) könnte jetzt den Boden nachhaltig verlassen. Es handelt sich um ein Unternehmen im Bereich der Genomik,…

Illumina Aktie: Kurszielanhebung

London (www.aktiencheck.de) - Rating-Update: Barclays stuft die Aktie von Illumina Inc. (ISIN: US4523271090, WKN: 927079, Ticker-Symbol: ILU, NASDAQ-Symbol: ILMN) weiterhin mit…

Illumina Aktie: Innovationen treiben Wachstum - RBC Capital bleibt optimistisch!

Toronto (www.aktiencheck.de) - Illumina-Aktienanalyse von RBC Capital Markets: Aktuelle Bewertung RBC Capital bleibt optimistisch in Bezug auf Illumina Inc. (ISIN: US4523271090, WKN:…

Illumina and Exxon Mobile have been highlighted as Zacks Bull and Bear of the Day

Illumina and Exxon Mobile have been highlighted as Zacks Bull and Bear of the Day.…

Global Gene Panel Market Size To Worth USD 4.46 Billion by 2033 | CAGR of 13.75%

The Global Gene Panel Market Size was Valued at USD 1.23 Billion in 2023 and the Worldwide Gene Panel Market…

Illumina: Trendbruch - Hoffnung auf Doppelboden - Chartanalyse

Düsseldorf (www.aktiencheck.de) - Illumina-Chartanalyse von HSBC Trinkaus & Burkhardt: Die Analysten von HSBC Trinkaus & Burkhardt nehmen in einer aktuellen Aktienanalyse…

UK’s venture capitalists brace for tax rises

Plus, corporate failures hit the cleantech industry and the EU’s top court sides with Illumina after a probe into $8bn…

Top EU court sides with U.S. biotech group Illumina in Grail legal battle By Investing.com

Top EU court sides with U.S. biotech group Illumina in Grail legal battle…

EU top court backs Illumina fight against EU probe into Grail deal By Reuters

EU top court backs Illumina fight against EU probe into Grail deal…

Illumina: Upgrade

New York (www.aktiencheck.de) - Rating-Update: Die Analysten von Argus Research stufen die Aktie von Illumina Inc. (ISIN: US4523271090, WKN: 927079, Ticker-Symbol:…

The Zacks Analyst Blog Highlights DaVita and Illumina

DaVita and Illumina are included in this Analyst Blog.…

Analyst Report: Illumina Inc

…

ILMNs TSO Comprehensive IVD Test Secures FDA Approval as CDx

Illuminas cancer biomarker test, TSO Comprehensive, gets approved by the FDA for use as CDx to match patients with targeted…

FDA approves Illuminas TruSight Oncology biomarker test

…

Global Cancer Biomarkers Market to Surge from USD 22.78 Billion in 2023 to USD 82.66 Billion by 2033, Achieving a CAGR of 13.76%

According to a research report published by Exactitude Consultancy, Companies covered:Abbott Laboratories Inc. - North America, Agilent Technologies Inc. -…

Illumina Looks Bullish (Technical Analysis)

…

Illumina (Monatschart): Ein antizyklischer Trade, aber einer mit Charme - Chartanalyse

Düsseldorf (www.aktiencheck.de) - Illumina-Chartanalyse von HSBC Trinkaus & Burkhardt: Die Analysten von HSBC Trinkaus & Burkhardt nehmen in einer aktuellen Aktienanalyse…

Illumina shares gain after TD Cowen upgrade By Investing.com

Illumina shares gain after TD Cowen upgrade…

Illumina (ILMN) Beats on Q2 Earnings, Lowers 2024 Sales View

Illuminas (ILMN) Q2 earnings and revenues surpass estimates in a challenging global macroeconomic environment.…

illumin Adds New Chief Revenue Officer and New Senior Vice President of Marketing to Leadership Team

New CRO and SVP Bring Deep Experience in Advertising, Agencies and Brands New CRO and SVP Bring Deep Experience in…

Illumina, Inc. (ILMN) Q2 2024 Earnings Call Transcript

…

Illumina expects full-year sales from core segment to decline on biotech funding crunch By Reuters

Illumina expects full-year sales from core segment to decline on biotech funding crunch…

Massive Kursverluste für das Wertpapier von Illumina (109,14 €)

Keinen Grund zur Freude haben die Investoren von Illumina : Der Titel verbilligt sich am Freitag deutlich. Der Anteilsschein von…

Illumina-Aktie gewinnt 4,35 Prozent (111,6930 €)

Die Aktie von Illumina zählt am Donnerstag zu den großen Gewinnern an der Börse. Das Wertpapier verteuert sich heute deutlich.…

Wall Street Analysts Think Illumina (ILMN) Could Surge 27.02%: Read This Before Placing a Bet

The consensus price target hints at a 27% upside potential for Illumina (ILMN). While empirical research shows that this sought-after…

Analyst Report: Illumina Inc

…

Illumina: Citi erhöht Rating auf "buy" - Aktienanalyse

New York (www.aktiencheck.de) - Illumina-Aktienanalyse von der Citigroup: Die Analysten der Citigroup stufen die Aktie von Illumina Inc. (ISIN: US4523271090, WKN:…

Illumina (ILMN) Buys Fluent, Grows in Single Cell Research

By integrating Fluents unique technology with Illuminas (ILMN) sequencing and informatics solutions, researchers are likely to gain access to a…

Global Cancer Diagnostics Market Size To Exceed USD 323.17 Billion By 2033 | CAGR of 8.71%

The Global Cancer Diagnostics Market Size was Valued at USD 140.25 Billion in 2023 and the Worldwide Cancer Diagnostics Market…

Gene-sequencing group Illumina sees $1.47 bn Q2 impairment charge linked to Grail By Investing.com

Gene-sequencing group Illumina sees $1.47 bn Q2 impairment charge linked to Grail…

Illumina to take $1.47 bln goodwill impairment charge related to Grail in Q2

Illumina said on Thursday it will take a goodwill impairment charge of $1.47 billion in the second quarter related to…

Illumina to take $1.47 billion goodwill impairment charge related to Grail in Q2 By Reuters

Illumina to take $1.47 billion goodwill impairment charge related to Grail in Q2…

Oncology Stocks: 8 Biggest NASDAQ Companies in 2024

The wide-ranging oncology market covers every area of cancer care, from diagnosis to treatment.Coming in only after cardiovascular disease, cancer…

Grail bets big on flagship cancer test after spin-off from Illumina

U.S. cancer diagnostic test maker Grail, which will list its shares on the Nasdaq on Tuesday after being spun out…

Grail bets big on flagship cancer test after spin-off from Illumina By Reuters

Grail bets big on flagship cancer test after spin-off from Illumina…

Global Nucleic Acid Isolation & Purification Market Size To Exceed USD 12.3 Billion by 2033 | CAGR Of 8.38%

The Global Nucleic Acid Isolation & Purification Market Size was Valued at USD 5.5 Billion in 2023 and the Worldwide…